Peter Ketelaar is the CEO of iPsomics, driving the commercialisation of stem-cell and genomics technologies developed at ERIBA into services that academic and pharmaceutical partners can rely on. With deep roots in pharmaceutical business development and technology transfer, he connects laboratory innovation with commercial application — turning technologies that work in the lab into accessible, market-ready tools for drug development.
LinkedIn
Tell us about your project and we'll bring patient-specific models and high-resolution genomics to your lab.
